REG - Schiehallion Fund Schiehallion - MNTN Schiehallion - MNTC - Directorate Change

AstraZenecaAnnouncement

02/09/2021 17:35

RNS Number : 5965K
  
Schiehallion Fund Limited (The)
  
02 September 2021
  
 

The Schiehallion Fund Limited
(the "Company")
Legal Entity Identifier: 213800NQOLJA1JCWXQ56
 
The Board is delighted to announce the appointments of David Chiswell and Richard Holmes as non-executive Directors of the Company with effect from 2 September 2021.
 
David Chiswell, Ph.D. has over 30 years' experience in the biotechnology industry. In 1990, Dr. Chiswell co-founded Cambridge Antibody Technology and served as its chief executive officer ("CEO") from 1996 to 2002. He served as CEO of Kymab Ltd from 2015 to 2018 and prior to that as CEO of Nabriva Therapeutics from 2009 to 2012. He served as a director of Arakis and non-executive chairman of Sosei, Arrow Therapeutics, Daniolabs, Nabriva Therapeutics and Kymab. Dr Chiswell is currently chairman of Albireo Pharma Inc and, Epsilogen Ltd and a board member of Avillion Bond 2 Development 2 GP.
 
Dr. Chiswell is also a past chairman of the UK BioIndustry Association and his contributions to the field were recognized in 2006 when he was awarded the OBE by HM the Queen for services to the biotechnology industry. 
 
Richard completed a BSc in Economics at London School of Economics and then a Masters at Warwick University. He worked in various marketing roles at Unilever in London, Paris and Milan from 1983 to 1995. He then moved to Boots Plc where he was marketing director and launched the Boots Advantage Card and set up Boots.com. In 2007, he moved to Guernsey to join the board of Specsavers Optical Group as group marketing director. He retired from full time work in 2018. He currently holds various non-executive positions, including Lok 'n Store Plc, Moorfields Eye Hospital and Citizens Advice Guernsey.
 
There is no further information required to be disclosed under Listing Rule 9.6.13.
 
 
Alter Domus (Guernsey) Limited
Company Secretary
2 September 2021
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
BOAELLFBFKLLBBK